Transcripts - Participants Matt Kapusta, Chief Executive Officer Ricardo Dolmetsch, President of R&D Sara Tabrizi, KOL Maria Cantor, Chief Corporate Affairs Officer Maria Cantor, Chief Corporate Affairs Officer Good morning, … Continue Reading
Read nowResearch - We’ve been discussing the potential for biotech to play some catchup to the broader market in our monthly webinars of late, and the move is … Continue Reading
PremiumResearch - UniQure (QURE) has essentially traded sideways since the company presented the first results from their ongoing open-label study of hemophilia gene therapy AMT-060 in January.
Read nowResearch - UniQure’s (QURE) AAV5-enabled AMT-060 looks good in its first human testing to date, with four of five Hemophilia B patients in the low-dose cohort fully … Continue Reading
Read nowResearch - UniQure (QURE) announced last Friday the appointment of a new CEO, Dan Soland, replacing long-time executive Jorn Aldag. The timing was atrocious.
PremiumResearch - Over the weekend, the scientific and investing communities had a first look at 1-year follow-up results for AMT-110, uniQure’s (QURE) gene therapy candidate for the treatment of Sanfilippo B.
Read nowResearch - UniQure’s (QURE) presentation of 1-year follow-up data from patients with Sanfilippo B (MPS IIIB) and treated with the gene therapy AMT-110 is only a week … Continue Reading
Read now
